Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19

Jing Xiong¹, Long Chen¹, Li Zhang², Lei Bao¹, and Yuan Shi¹

Abstract
During the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many critically ill patients died of severe pneumonia, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome. To date, no specific treatments have been proven to be effective for coronavirus disease 2019 (COVID-19). In the animal models and clinical applications, mesenchymal stromal/stem cells (MSCs) have been shown safety and efficacy for the treatment of respiratory virus infection through their abilities of differentiation and immunomodulation. Besides, possessing several advantages of MSC-derived extracellular vesicles (EVs) over MSCs, EV-based therapy also holds potential therapeutic effects in respiratory virus infection. In this review, we summarized the basic characteristics and mechanisms of COVID-19 and MSCs, outlined some preclinical and clinical studies of MSCs or MSC-EVs for respiratory virus infection such as influenza virus and SARS-CoV-2, shed light on the common problems that we should overcome to translate MSC therapy into clinical application, and discussed some safe issues related to the use of MSCs.

Keywords
mesenchymal stromal cells, coronavirus disease 2019, clinical translation

Introduction
COVID-19
Since the end of December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emerged in Wuhan city, China, and has spread to other provinces of China and other counties quickly¹,². Human to human transmission was confirmed subsequently³. On 11 March 2020, the World Health Organization (WHO) officially declared the situation as a pandemic⁴. As of 21 Dec 2020, the novel virus has infected more than 75,700,000 people with more than 1,690,000 deaths worldwide, over 200 countries have been involved in this public health threat⁵. As with SARS-CoV and the Middle East respiratory syndrome (MERS)-CoV, SARS-CoV-2 is classified as a β CoV of group 2B⁶. It enters the host cell by its spike protein binding to the receptors identified as angiotensin-converting enzyme 2 (ACE2), which are primarily expressed in the lung epithelial cells⁷. Besides, study showed that the cellular serine protease TMPRSS2 for SAR-CoV-2 Spike protein priming is also important for entry into target cells⁸ (Fig. 1). The clinical symptoms of coronavirus disease 2019 (COVID-19) vary from asymptomatic to symptomatic, and the severe cases have been reported to be around 14% of all cases, and around 6% and 3% presented with critical and fatal outcomes, respectively⁹. Typical clinical symptoms of COVID-19 are fever, cough, dyspnea, and pneumonia. Complications during hospitalization include acute respiratory distress syndrome (ARDS), RNAemia, acute cardiac injury, secondary infection, acute kidney injury, shock, and multiple organ dysfunction syndrome (MODS)¹⁰,¹¹. So far, there are no effective treatments for COVID-19. Several potential drug candidates, including lopinavir/ritonavir, nucleoside analogues, neuraminidase inhibitors, remdesivir, DNA synthesis inhibitors (such as tenofovir disoproxil and lamivudine), chloroquine, and Chinese...
traditional medicines, have been proposed\textsuperscript{12,13}. Besides, immunological therapy may have a role for COVID-19 as well, as SARS-CoV-2 infection can induce a cytokine storm in the lung, such as interleukine-2 (IL-2), IL-6, IL-7, GSCF, IP10, MCP1, MIP1A, and tumor necrosis factor-\(\alpha\) (TNF-\(\alpha\)), which leads to ARDS\textsuperscript{10}. Therefore, avoiding the cytokine storm is a key step for the treatment of COVID-19. However, systemic corticosteroids may reduce the activity of immune system while inhibiting the cytokine storm\textsuperscript{14}. In view of the rapid spread of SARS-CoV-2 and the increasing number of death worldwide, the potential of treatment lies in identifying novel therapeutics aimed at the patients with COVID-19 most likely to respond.

**Mesenchymal Stromal Cell-Based Therapy**

Mesenchymal stromal cells (MSCs) are non-hematopoietic, multipotent stromal precursor cells that can be derived from many tissues, including bone marrow (BM), adipose, dental pulp, placenta, cord blood, and matrix\textsuperscript{15}. Possessing the ability of differentiating into osteoblasts, adipocytes, and chondroblasts \textit{in vitro}, MSCs adhere to plastic under standard tissue conditions and express CD105, CD90, and CD73, yet not express other markers such as CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR surface molecules\textsuperscript{16}. The minimal criteria for MSCs was firstly defined by the International Society for Cellular Therapy (ISCT) in 2006\textsuperscript{16}, followed by several updates mainly focusing on the refinement of standards for therapeutic efficacy\textsuperscript{17–19}. It is known that MSCs are able to activate cell proliferation, prevent apoptosis, and improve regenerative responses by releasing growth factors and cytokines along with extracellular vesicles (EVs). In addition to the capability of differentiating into the particular phenotype of the damaged cells, such as lung epithelial and endothelial cells, which result in edema reduction and barrier repairation, MSCs also exert paracrine and immunoregulatory functions by cell to cell contact or secreting soluble factors. On one hand, MSCs are able to suppress CD4+ T helper cells, CD8+ cytotoxic T cells, and macrophages, and induce their differentiation into regulatory T cells (Treg) subsets and anti-inflammatory macrophages. Besides, they also inhibit the activity of dendritic cells (DCs) and natural killer (NK) cells to regulate immune response. On the other hand, MSCs can release soluble factors, such as indoleamine 2,3 dioxygenase (IDO), prostaglandin E2 (PGE-2), and nitric oxide (NO), to realize immunomodulation\textsuperscript{20}. Importantly, MSCs reveal low

\[\text{Figure 1. The spike protein of SARS-CoV-2 mediates the entry of the virus into target cells via the ACE2 receptor, which leads to cytokine storm. ARDS: acute respiratory distress syndrome; ACE2: angiotensin-converting enzyme 2; MODS: multiple organ dysfunction syndrome; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.}\]
immunogenicity and low tumorigenicity, and can be isolated and expanded extensively without damage to their self-renewal or multipotency properties. For decades, MSC therapy has been used for an array of ailments, especially in the immune-mediated inflammatory diseases, such as systemic lupus erythematosus (SLE) and graft versus-host disease (GVHD). Following intravenous infusion, MSCs are rapidly trapped in lungs, and a small amount of MSCs may recirculate to inflammatory or injured sites. The migration of MSCs to the sites of injury or inflammation also plays an important role in its therapeutic effect. It is known that MSCs express a broad range of chemokine and growth factor receptors, such as CX chemokine receptors 1 and 2 (CXCR1 and CXCR2), CXCR4, CC chemokine receptor 1 (CCR1), CCR2, and platelet-derived growth factor (PDGF). With the damage of organ or tissue, the released cytokines cause migration of MSCs to sites of inflammation and injury, thus stimulate tissue repair. Therefore, in light of the pathogenesis of SARS-CoV-2, MSCs therapy holds great promise for the treatment of COVID-19 by inhibiting the cytokine storm and facilitating tissue repair and regeneration (Fig. 2).

**MSCs in Respiratory Virus Infection in Preclinical Studies**

Multiple studies have shown beneficial effects of MSCs on preclinical models for ARDS and sepsis via paracrine section to modulate pathobiological pathways, including inflammation, endothelial and epithelial cell injury, alveolar fluid clearance (AFC), antimicrobial activity, and apoptosis. However, little is known about MSCs therapy in the treatment of respiratory virus infection. In mice model, the effects of MSC therapy for influenza were inconsistent. In a preclinical study by Chan et al., mice infecting with influenza A/H5N1 were treated with BM-MSCs, the results showed a clinically significant reduction in lung pathology and increased survival rate among the aged mice, while no improved survival or histopathology in young mice. These reflect age-related differences in mechanisms of lung pathology and repair. In vitro, when H5N1 483/97-infected alveolar epithelial cells (AECs) were co-cultured with MSCs, a decrease in the impairment of AFC, reduction of the increased alveolar protein permeability (APP), and reduced proinflammatory cytokine responses were observed.
in AECs. Besides, angiopoietin-1 (Ang-1) and keratinocyte growth factor (KGF) were secreted by MSCs co-cultured with H5N1-infected AECs, which partly reduced MSC-mediated impairment of AFC and APP.\(^{29}\) In Hong Kong, \textit{in vitro} study of the lung injury model showed that umbilical cord (UC)-MSCs were more effectively in correcting impaired AFC, APP, and major epithelial ion transporter expression of H5N1-infected human AECs partly through Ang-1 and Hepatocyte Growth Factor (HGF) secretion compared with BM-MSCs or infected AEC alone. Besides, both UC-MSCs and BM-MSCs reduced H5N1 induction of several major pro-inflammatory cytokines and enhanced responses of anti-inflammatory cytokines in infected AECs compared with AECs alone. Particularly, these responses were weaker in infected AECs with BM-MSCs compared to AECs with UC-MSCs. Furthermore, the authors also found that UC-MSC secretome and UC-MSC exosomes restored H5N1-impaired AFC and APP of infected AECs. However, \textit{in vivo} assay, only marginal therapeutic benefits of UC-MSCs in mice were observed, such as slightly improvement of body weight, lower concentration of Evans blue dye, and several reduced pro-inflammatory cytokines and chemokine protein levels of the bronchoalveolar lavage fluid (BALF) from H5N1 infected mice with UC-MSC treatment. And no beneficial effects of UC-MSC treatment on survival and anti-virus were shown.\(^{30}\) In the study reporting on H9N2 avian influenza virus-induced acute lung injury in mice, infusion of BM-MSCs was associated with higher survival rate, lower dry weight ratios of lung, reduced airspace inflammation, improved lung hypoxemia and histopathology, reduced chemokines and proinflammatory cytokines levels, and decreased protein expression of CD14, TLR4, ERK, and JNK in the lung tissue as compared to the control group. These findings demonstrated that MSCs results in improvements in both pulmonary inflammation and lung tissue organization.\(^{31}\) However, some studies have shown that administration of MSCs in a prophylactic or therapeutic regimen failed to improve outcomes in experimental severe influenza.\(^{32,33}\) The conflicting observations of MSCs therapy for respiratory virus infection may result from different virus strains and experimental designs.

**Clinical Application of MSCs in Respiratory Virus-Induced Lung Injury**

Although compelling evidence of ARDS in patients have shown safety and efficacy of MSC administration, the clinical trial of the therapeutic effect of MSCs in respiratory virus-induced lung injury is not currently extensive.

Chen et al. conducted a single center study of menstrual-blood-derived MSCs in patients with H7N9-induced ARDS, in which one million per kilogram of body weight for each time of MSCs were infused at the acute phase or late stage of ARDS in 17 voluntary patients with moderate to severe H7N9-induced ARDS. The results showed that death rate was significantly reduced in the MSCs treatment group compared with the control group (17.6% vs 54.5%, \(P = 0.006\)), with no MSC-infusion-related acute toxicities or seriously adverse events were observed in any of these patients. Besides, during the five years’ follow-up, significant improvement in lung function at each follow-up was found in four patients with MSC transplantation.\(^{34}\) Currently, there is one published study investigating the therapeutic effect of MSCs in COVID-19, in which seven laboratory-confirmed COVID-19 patients, including one critically severe type, four severe types, and two common types were enrolled for MSCs transplantation intravenously, and three severe types were enrolled for placebo control. The results of the trial suggested that the pulmonary function and symptoms of these seven patients were significantly improved in two days after treatment. In 10 days after treatment, two common and one severe patient were recovered and discharged. Besides, increased peripheral lymphocytes, decreased C-reactive protein (CRP), and disappeared overactivated cytokine-secreting immune cell CXCR3\(^+\)CD4\(^+\)T cells, CXCR3\(^+\)CD8\(^+\)T cells, and CXCR3\(^+\)NK cells were observed in 3-6 days after treatment. Furthermore, compared with the control group, the MSC treatment group had increased CD14\(^+\)CD11c\(^+\)CD11b mid-regulatory DC population, decreased TNF-\(\alpha\), and increased IL-10. No infusion-related or allergic reaction were observed after treatment. More importantly, the gene expression profile showed that MSCs were ACE2 and TMRPRSS2 negative, indicating that MSCs were free from SARS-CoV-2 infection.\(^{35}\)

In another randomized control trial (RCT) by Shu et al, 41 patients with severe COVID-19 were randomly divided into either the standard treatment group (29 patients) or the standard treatment group plus human UC-MSC (hUC-MSC) infusion group (12 patients). In the hUC-MSC treatment group, all patients improved and were discharged, while four patients in the control group deteriorated to critical illness and received invasive ventilation, and three of them died, with a 28-day mortality rate of 10.34%. In the hUC-MSC group, the time to clinical improvement was shorter, CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the lymphocyte count to return to the normal range was significantly faster, and lung inflammation absorption was significantly shorter on CT imaging as compared to the control group. No adverse reactions were observed in all patients who received hUC-MSC treatment.\(^{36}\) These data suggest that MSC therapy was safe and effective for the treatment of COVID-19.

**Researches on MSC Derived Extracellular Vesicles (EVs) in Respiratory Virus Infection**

Emerging studies have shown that MSC-derived EVs, which consist of the lipid bilayer with transmembrane proteins and contain cellular components such as lipids, cytosolic proteins, DNA, RNA, and microRNAs (miRNAs), can mitigate acute lung injury (ALI).\(^{37}\) In injured tissue, MSC-EVs interact between stem and injured cells, and realize tissue repair by transferring proteins, bioactive lipids, mRNA, and microRNA from MSCs to injured cells.\(^{38}\) In addition to the similar
therapeutic effects as MSCs, MSC-EVs offer several advantages over MSCs, including low immunogenicity and simple storage.

Khatari et al. performed a study in a pig model of influenza virus, in which EVs from swine BM-MSCs were generated for in vitro and in vivo experiments. After incorporating into lung epithelial cells (LECs) in vitro, MSC-EVs had shown to reduce influenza virus replication and significantly inhibit the apoptosis of influenza-infected LEC. In vivo, MSC-EVs were administered intratracheally in influenza-infected pigs, the results revealed that minor infiltration of inflammatory cells and less inflammatory lesions were showed in lungs of pigs administered with MSC-EVs compared with the control group. Besides, virus titers and inflammatory cytokines production in the lung lysate and virus shedding in nasal swabs at day 3 post-EV administration were also lower in the EV-administrated group, while the levels of the anti-inflammatory cytokine IL-10 were slightly higher in the EV-administered group, as compared to the control group. These data suggested that, in addition to the anti-influenza and anti-inflammatory properties, MSC-EVs also attenuated influenza virus-induced ALI in a pig model.

Role of MSC-Derived Exosomes in the Treatment of COVID-19

The term EVs comprises three types of vesicles namely exosomes, microvesicles (MVs), and apoptotic bodies (ABs) according to the international society for extracellular vesicles (ISEV). Of which, exosomes have size between 30 and 120 nm in diameter that participate in several pathological conditions. A prospective cohort study aimed at evaluating the safety and efficacy of exosomes (ExoFloTM) derived from allogeneic BM-MSCs for the treatment of severe COVID-19 and the results showed improvements in patients’ clinical status and oxygenation, significant reduction in levels of the acute phase reactants CRP, ferritin, D-Dimer, and absolute neutrophil count, and significant increase in absolute lymphocyte count, with no adverse events observed within 72 hours of ExoFlo administration. Further studies are needed to testify the safety and efficacy of exosomes in the treatment of COVID-19. The preclinical and clinical studies investigating the effect of MSCs/MSC-derived EVs in respiratory virus infection are summarized in Table 1.

Clinical Translation of MSCs

MSCs Sources

The most common source of MSCs in respiratory disease has been BM. But BM-MSCs are harvested by a highly invasive procedure. Besides, aging is associated with decreased differentiation potential, proliferation capacity, cell number, and maximal life span of BM-MSCs, which limits their use in the clinical settings. Gradually, more attention has been paid to adipose-derived (AD)-MSCs and UC-MSCs. A large amount of AD-MSCs can be easier acquired by liposuction. Furthermore, AD contains more than a thousand times of more MSCs, which may present a higher proliferation rate. Likewise, UC-MSCs have higher proliferation rate, can be extracted noninvasively, and can grow more rapidly compared with BM-MSCs that allows the generation of high numbers of early passage MSCs. Unlike embryonic stem cells (ESCs), UC-MSC is an after birth tissue and is considered medical waste. Besides, the donor conditions of UC-MSCs are more uniform, thus reduce variability and enhance potency. Nowadays, perinatal-derived cells (PDCs) including UC-MSCs have drawn public attention due to their early embryological origin and they possess unique plasticity and differentiation properties. In vitro, PDCs from both maternal and fetal tissues do not induce immune response, which makes them attractive for allogeneic transplantation. All these different types of stem cells have been shown efficacy in preclinical and clinical studies.

MSCs Dosage Regimens

MSCs can be administrated either intratracheally or intravenously. However, there is no evidence to prove which one is superior. And no study regarding the proper number of cells. In the STem cells for ARDS Treatment (START) phase 1 trial, three doses were administrated in three cohorts (1 × 106 cells/kg, 5 × 106 cells/kg, and 10 × 106 cells/kg predicted body weight, respectively), and the maximal dosage was well tolerated by patients. In the further START phase 2 trial, subjects were directly administrated maximum tolerable dose of MSCs, and the results showed safety of this approach. However, the optimum dose of MSC-based therapy remains to be determined.

Cell Manufacture and Storage

After cryopreservation, storage and transport, MSCs must retain viability and efficacy to be effective in clinical application. Administration immediately following thawing the cryopreserved MSCs and suspending them in plasmalyte. In this approach, MSCs are given with Dimethyl sulfoxide (DMSO), which has been most frequently used for years as a cryoprotectant agent. However, its use has been reported to induce some complications, including vomiting, abdominal pain or even fatal cardiopulmonary events, after infusion of cryopreserved bone marrow or cord blood. However, some data indicated that the thawing and washing to remove DMSO resulted in a substantial loss of cells. In the START phase 1 and phase 2 trials, MSCs were thawed and washed to remove DMSO, and then resuspended in plasmalyte before intravenous administration. The results have shown that this approach can retain the efficacy of the MSCs in these studies.

Administration Routes

Concerning the MSC-based therapy for COVID-19, whether intravenous route is the best choice is not yet clear. Local
| Study          | Model/patient                  | Treatment                          | Mechanism                                                                 | Reference |
|---------------|--------------------------------|------------------------------------|---------------------------------------------------------------------------|-----------|
| Chan et al    | H5N1 influenza virus-infected | Human BM-MSCs                       | In vitro                                                                  | 29        |
| (2016)        | mice                           |                                    | AFC and APP, IL-1β, RANTES, IL6, IL8, and IP10 mRNA levels, transporters of CFTR, α1Na, and K-ATPase |           |
|               | H5N1 influenza A viruses induced AECs |                                    | Ang-1 and KGF                                                            |           |
|               |                                 |                                    | Survival and body weight in aged mice                                      |           |
|               |                                 |                                    | Wet-to-dry lung weight, Evans blue dye in the lungs, and the concentration of total protein, most cytokine, and chemokine of the BALF in all mice. |           |
|               |                                 |                                    | Peribronchial, perivascular, and overall histopathology scores.           |           |
| Loy et al     | Mouse ALI                      | Human BM-MSCs and Human UC-MSCs    | Restoration of AFC and APP (BM-MSCs, UC-MSCs, and UC-MSC secretome and exosomes) | 30        |
| (2019)        | Influenza A/H5N1 virus induced |                                    | ENaC, Na+, K+-ATPase, and CFTR (both BM-MSCs and UC-MSCs)                |           |
|               | AECs                           |                                    | IFN-γ, IL-6, IL-1β, IP-10, MCP-1, and RANTES (both BM-MSCs and UC-MSCs)  |           |
|               |                                 |                                    | IL-4, IL-10, IL-11, IL-13, and IL-1RA (both UC-MSCs and BM-MSCs)          |           |
|               |                                 |                                    | In vivo                                                                  |           |
|               |                                 |                                    | Body weight (UC-MSCs)                                                   |           |
|               |                                 |                                    | Evans blue dye (UC-MSCs)                                                |           |
|               |                                 |                                    | IP-10, MCP-1, RANTES, TNF-α, IL1-β, IL-6 and IL-8 protein levels (UC-MSCs) |           |
| Li et al      | Mice                           | BM-MSCs of mice                    | Survival rate                                                             | 31        |
| (2016)        | H9N2 avian influenza virus-induced ALI |                                    | Lung weights and lung wet: dry weight ratios                             |           |
|               |                                 |                                    | Airspace inflammation                                                    |           |
|               |                                 |                                    | Lung histopathology                                                      |           |
|               |                                 |                                    | PaO₂, SaO₂, and pH values                                               |           |
|               |                                 |                                    | PaCO₂                                                                     |           |
|               |                                 |                                    | GM-CSF, MCP-1, KC, MIP-1α, and MIG in both BALF and serum                |           |
|               |                                 |                                    | IL-1α, IL-6, IL-10, TNF-α, and IFN-γ in both BALF and serum              |           |
|               |                                 |                                    | CD14, TLR4, ERK and JNK protein in the lung tissue                       |           |
| Chen et al    | Patients with H7N9-induced ARDS| Human menstrual-blood-derived MSCs | Survival rate                                                             | 34        |
| (2020)        |                                |                                    | PCT, ALT, sCr, CK, PT, D-Dimer                                          |           |
|               |                                |                                    | In 4 patients with MSC transplantation during follow-up                 |           |
|               |                                |                                    | Hemoglobin levels                                                       |           |
|               |                                |                                    | PT                                                                        |           |
|               |                                |                                    | Improvement in both lung function and lesions on CCT                     |           |
|               |                                |                                    | Plasma CRP in one critically severe patient                             | 35        |
|               |                                |                                    | Oxygen saturation                                                        |           |
|               |                                |                                    | Lymphocyte                                                               |           |
|               |                                |                                    | ALT, CK activity and myoglobin                                           |           |
|               |                                |                                    | Improvement on CCT                                                       |           |
|               |                                |                                    | Regulatory T cells and dendritic cell in the severe and critically severe patients |           |
|               |                                |                                    | CD14+CD11c+CD11bmid-regulatory dendritic cell and disappearance of overactivated T cells and NK cells in the critically severe patients. |           |
|               |                                |                                    | TNF-α                                                                    |           |
|               |                                |                                    | IL-10                                                                    |           |

(continued)
administration can help deliver paracrine mediators to the diseased sites directly, such as intratracheal or intramuscular injection. However, the therapeutic benefit may be hindered because of insufficient retention and survival of transplanted MSCs at the site of administration, as some of the administered cells remain at the site of injection in the hours following transplantation. Alternatively, systematic administration of MSCs, such as intravenous injection, also brings some challenges, including the insufficient residence time and homing of MSCs to the target tissues limits the therapeutic effects, and the instant blood-mediated inflammatory reaction (IBMIR) following MSC contact with human serum, which was firstly reported by Moll et al. after infusion of BM- and PT-derived clinical MSC products. Moll et al. also firstly described the coagulation-related issues of MSC therapies for COVID-19.

### Safety Aspects Considering Infusion of MSC from Different Tissue Sources in COVID-19

Firstly, abnormal coagulation parameters have been reported in many severely and critically ill patients with COVID-19, and disseminated intravascular coagulation (DIC) was common in severe respiratory failure patients with COVID-19, which was usually associated with poor prognosis. However, MSCs express variable degree of tissue factor (TF) on their surfaces and are procoagulant in the presence of blood or plasma, and infusion of MSCs systematically may adversely trigger the IBMIR in patients, which was firstly reported by Moll et al. after infusion of BM- and PT-derived clinical MSC products. Moll et al. also firstly described the coagulation-related issues of MSC therapies for COVID-19. TF expression and triggering of IBMIR by MSC products depend on the tissue source or starting material the MSC products were derived from. And AT- and PT-derived products express higher degree of TF and have reduced hemocompatibility than BM-MSCs, with substantial donor variability and culture passage-dependent TF induction. Moreover, tissue factor expression changes over culture time, and handling conditions and growth media likely also affect procoagulant activity. Therefore, before administering MSCs intravenously, it is essential to testing the cells initially and selecting MSCs with low tissue factor/low procoagulant activity. Besides, cells with high tissue factor expression may also be subjected to preconditioning before administration to reduce tissue factor expression. Furthermore, it is necessary to develop administration protocols for delaying timing of administration to after resolution of coagulopathy or incorporating anticoagulants such as heparin to maximize therapeutic effect. Particularly,
alternative routes of cell administration in patients with COVID-19 such as topical application of intramuscular injection are being increasingly explored. Secondly, the source of MSCs should be comply with the national standards to ensure cell viability and quality and sterility of stem cells. MSC companies and hospitals treating patients should equip adequate facilities with qualified personnel to provide proper dose regimens, optimal route and method of administration, and MSC quality and counts. Thirdly, some studies have demonstrated that MSCs are susceptible to influenza virus. Thanunchai et al. reported that highly pathogenic avian influenza H5N1 virus could infect and replicate in MSCs, and virus infection resulted in apoptosis and losing of the immunoregulatory activity of MSCs. Similarly, known influenza virus α-2,3 and α-2,6 sialic acid receptors were shown to express in BM-MSCs of pigs to support replication of swine and human influenza viruses, and viral infection of MSCs resulted in cell lysis and proinflammatory cytokine production. However, no in vivo study has demonstrated the direct infection of influenza viruses to MSCs. The interaction between MSCs and virus can be characterized as double-edge sword, therefore, the safety of administration of MSCs should be ensured by screening the presence of viruses both in donors and recipients. Fourthly, precautions should be taken during the MSCs administration, medical health workers should monitor closely the occurrence of complications, such as embolism and allergic reaction, and take countermeasures actively. Fifthly, to ensure the safety of MSCs therapy, clinical studies should be carefully designed and the administration of MSCs should apply to the indications.

Conclusions

By far, many clinical trials have been initiated worldwide, among them, bone marrow, umbilical cord (including umbilical cord blood and Wharton’s jelly), adipose tissue, menstrual blood, and some selected MSC therapy products of companies are the primary MSC sources. Based on the promising results of MSCs or MSC-derived EVs for respiratory virus infection in preclinical and clinical studies both in vitro and in vivo, and MSCs for COVID-19 treatment during pandemic, MSC-based therapy holds great promise and possibility for COVID-19. However, there were inconsistency of MSC-based therapy for influenza virus infection among some preclinical experiments, and problems and challenges for its clinical use still exist, including high cost, challenges associated with administration of MSCs, and the inevitable safe issues. Particularly, during the pandemic period, it is necessary to develop safe and accessible MSC-based therapy for low/middle income countries. Furthermore, to facilitate clinical translation, MSCs need to be manufactured with standard procedures in terms of cell delivery, cryopreservation/thawing, etc. Further research into the effect of MSC-based therapeutics for the treatment of moderate-severe phases of COVID-19 is essential, and novel approaches, such as MSC-derived exosomes, should be explored as well. What deserves expecting is that many trials of MSCs for COVID-19 are ongoing worldwide.

Author Contributions

JX drafted the initial manuscript. LC revised the manuscript. LZ designed and completed the table and the figures. LB and YS conceptualized the study and critically reviewed the manuscript for importantintellectual content. All authors reviewed and approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) declared no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Yuan Shi https://orcid.org/0000-0002-4571-4424

References

1. Na Z, Dingyu Z, Wenling W, Xingwang L, Bo Y, Jingdong S, Xiang Z, Baoying H, Weifeng S, Roujian L, Peihua N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
2. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020;92(4):401–402.
3. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.
4. World Health Organization. WHO Virtual press conference on COVID-19 [Internet]. Geneva: WHO; 2020 [cited 2020 Mar 16]. Available from: https://www.who.int/docs/default-source/coronavirus/transcripts/who-audio-emergencies-coronavirus-press-conference-full-and-final11mar2020.pdf?sfvrsn=cb432bb3_2
5. World Health Organization. (WHO. Novel Coronavirus (2019-nCoV). Weekly epidemiological update - 21 December 2020 [Internet]. Geneva: WHO; 2020 [cited 2020 Dec 21]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—21-december-2020
6. Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266.
7. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, et al. A pneumonia
outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.

8. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. 2020. bioRxiv:20200123.929042.

9. Moll G, Drzeniek N, Kamihie-Milz J, Geissler S, Volk HD, Reinke P. MSC therapies for COVID-19: importance of patient coagulopathy, thrombophrophylaxis, cell product quality and mode of delivery for treatment safety and efficacy. Front Immunol. 2020;11:1091.

10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

11. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020;382:1708–1720.

12. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71.

13. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71.

14. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.

15. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: immunosuppressive capabilities of mesenchymal stromal/stromal cells in a preclinical setting. Stem Cells Int. 2013;2013:678063.

16. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13.

17. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25(11):2739–2749.

18. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marin I, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 2006;8(4):315–317.

19. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L; MSC Committee of the International Society for Cellular Therapy (ISCT). Immunological characterization of multipotent mesenchymal stromal cells-the international society for cellular therapy (ISCT) working proposal. Cytotherapy. 2013;15(9):1054–1061.

20. Galipeau J, Krampera M. The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy. 2015;17(2):125–127.

21. Barry FP, Murphy JM, English K, Mahon BP. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev. 2005;14(3):252–265.

22. Casiraghi F, Remuzzi G, Abbate M, Perico N. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev. 2013;9(1):65–79.

23. Polak JM, Bishop AE. Stem cells and tissue engineering: past, present, and future. Ann N Y Acad Sci. 2006;1068:352–366.

24. Yamahara K, Hamada A, Soma T, Okamoto R, Okada M, Yoshihara S, Ishihara K, Ikegame K, Tamaki H, Kaida K, Inoue T, et al. Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial. BMJ Open. 2019;9(7):e026403.

25. Wang D, Zhang H, Liang J, Li X, Feng X, Wang H, Hua B, Liu B, Lu L, Gilkeson GS, Silver RM, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant. 2013;22(12):2267–2277.

26. Sensebe L, Fleury-Cappellesso S. Biodistribution of mesenchymal stem/stromal cells in a preclinical setting. Stem Cells Int. 2013;2013:678063.

27. Eseonu OI, De Bari C. Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis. Rheumatology (Oxford). 2015;54(2):210–218.

28. Thanunchai M, Kanrai P, Wiboon-Ut S, Puthavathana P, Hongeng S, Thitithayanont A. Tropism of avian influenza A (H5N1) virus to mesenchymal stem cells and CD34+ hematopoietic stem cells. PLoS One. 2013;8(12):e81805.

29. Chan MC, Kuok DI, Leung CY, Hui KP, Valkenburg SA, Lau EH, Nicholls JM, Fang X, Guan Y, Lee JW, Chan RW, et al. Human mesenchymal stem cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A. 2016;113(13):3621–3626.

30. Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, Peiris JSM, Chan MCW. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza a(h5n1) virus-associated acute lung injury. J Infect Dis. 2019;219(2):186–196.

31. Li Y, Xu J, Shi W, Chen C, Shao Y, Zhu L, Lu W, Han X. Mesenchymal stem cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7(1):159.

32. Darwish I, Banner D, Mubareka S, Kim H, Besla R, Kelvin DJ, Kain KC, Liles WC. Mesenchymal stromal cell therapy fails to improve outcomes in experimental severe influenza. PLoS One. 2013;8(8):e71761.

33. Gotts JE, Abbott J, Matthey MA. Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal stem cell therapy. Am J Physiol Lung Cell Mol Physiol. 2014;307(5):L395–L406.

34. Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, Chen L, Gao H, Lu X, Yu L, Dai X, et al. Clinical study of mesenchymal stem
cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering (Beijing). 2020;6(10):1153–1161. doi:10.1016/j.eng.2020.02.006. [Epub ahead of print]

35. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–228.

36. Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, Ji N, Zheng Y, Chen X, Shi L, Wu M, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361.

37. Wang J, Huang R, Xu Q, Zheng G, Qiu G, Ge M, Shu Q, Xu J. Mesenchymal stem cell-derived extracellular vesicles alleviate acute lung injury via transfer of miR-27a-3p. Crit Care Med. 2020;48(7):e599–e610. doi:10.1097/CCM.0000000000004315. [Epub ahead of print]

38. Camussi G, Deregibus MC, Cantaluppi V. Role of stem-cell-derived microvesicles in the paracrine action of stem cells. Biochem Soc Trans. 2013;41(1):283–287.

39. Fujita Y, Kadota T, Araya J, Ochiya T, Kuwano K. Clinical application of mesenchymal stem cell-derived extracellular vesicle-based therapeutics for inflammatory lung diseases. J Clin Med. 2018;7(10):E355.

40. Khatri M, Richardson LA, Meulia T. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther. 2018;9(1):17.

41. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkinson-Smith GK, Ayre DC, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.

42. Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev. 2020;29(12):747–754.

43. Lathrop MJ, Brooks EM, Bonenfant NR, Sokocevic D, Borg ZD, Goodwin M, Loi R, Cruz F, Dunaway CW, Steele C, Weiss DJ. Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway. Stem Cells Transl Med. 2014;3(2):194–205.

44. Cruz FF, Borg ZD, Goodwin M, Sokocëvic D, Wagner DE, Coffey A, Antunes M, Robinson KL, Mitsialis SA, Kourismañas S, Thane K, et al. Systemic administration of human bone marrow-derived mesenchymal stromal cell extracellular vesicles ameliorates aspergillus hyphal extract-induced allergic airway inflammation in immunocompetent mice. Stem Cells Transl Med. 2015;4(11):1302–1316.

45. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33(6):919–926.

46. Yu JM, Wu X, Gimble JM, Guan X, Freitas MA, Bunnell BA. Age-related changes in mesenchymal stem cells derived from rhesus macaque bone marrow. Aging Cell. 2011;10(1):66–79.

47. McIntyre LA, Moher D, Fergusson DA, Sullivan KJ, Mei SH, Lalu M, Marshall J, McLeod M, Griffin G, Grimshaw J, Turgeon A, et al. Efficacy of mesenchymal stromal cell therapy for acute lung injury in preclinical animal models: a systematic review. PLoS One. 2016;11(1):e0147170.

48. Curley GF, Jerkic M, Dixon S, Hogan G, Masterson C, O’Toole D, Devaney J, Lafey JG. Cryopreserved, xeno-free human umbilical cord mesenchymal stem cells reduce lung injury severity and bacterial burden in rodent escherichia coli-induced acute respiratory distress syndrome. Crit Care Med. 2017;45(2):e202–e212.

49. Fong CY, Gauthaman K, Cheytraiavendran S, Lin HD, Biswas A, Bongo A. Human umbilical cord Wharton’s jelly stem cells and its conditioned medium suprathematoipoietic stem cell expansion ex vivo. J Cell Biochem. 2012;113(2):658–668.

50. Parolini O, Soncini M. Human placenta: a source of progenitor/stem cells? J.Reproduktionsmed Endokrinol, 2006;3(2):117–126.

51. Papait A, Vertua E, Magatti M, Ceccariglia S, Munari SD, Silini AR, Sheleg M, Ofir R, Parolini O. Mesenchymal stromal cells from fetal and maternal placenta possess key similarities and differences: potential implications for their applications in regenerative medicine. Cells. 2020;9(1):127.

52. Wolbahn S, Peterbauer A, Fahmehr M, Hennerbichler S, Grienven MV, Stadler G, Redl H, Gabriel C. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Tissue Eng. 2007;13(6):1173–1183.

53. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol. 2010;88(8):795–806.

54. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24–32.

55. Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gots JW, Wiener-Kronish JP, Bajwa EK, Donahoe MP, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–162.

56. Ruiz-Delgado GJ, Mancías-Guerra C, Tamez-Gómez EL, Rodríguez-Romo LN, López-Otero A, Hernández-Arizpe A, Gómez-Almaguer D, Ruiz-Argüelles GJ. Dimethyl sulfoxide-induced toxicity in cord blood stem cell transplantation: report of three cases and review of the literature. Acta Haematol. 2009;122(1):1–5.

57. Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, Biasio MD, Heinelt M, Reeve B, Abdi R, Alturki M, et al. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv. 2020;6(30):eaba6884.
58. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.

59. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.

60. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 2020;18(4):844–847.

61. Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, Tang C, Zhang N, Zhong N, Li S. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020;7(5):e362–e363.

62. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.

63. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, Paassen JV, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147.

64. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13.

65. Moll G, Ankrum JA, Kamhihe-Milz J, Bieback K, Ringdén O, Volk HD, Geissler S, Reinke P. Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med. 2019;25(2):149–163.

66. Caplan H, Olson SD, Kumar A, George M, Prabhakara KS, Wenzel P, Bedi S, Toledano-Furman NE, Triolo F, Kamhieh-Milz J, Moll G, et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol. 2019;10:1645.

67. Moll G, Rasmusson-Duprez I, Bahr LV, Connolly-Andersen A, Elgue G, Funke L, Hamad OA, Lönnes H, Magnusson PU, Sanchez J, Teramura Y, et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cell Res Ther. 2019;10(1):322.

68. Moll G, Ignatowicz L, Catar R, Luecht C, Sadeghi B, Hamad O, Jungebluth P, Dragan D, Schmidtchen A, Ringdén O. Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua. Stem Cells Dev. 2015;24(19):2269–2279.

69. Christy BA, Herzig MC, Montgomery RK, Delavan C, Bynum JA, Reddock KM, Cap AP. Procoagulant activity of human mesenchymal stem cells. J Trauma Acute Care Surg. 2017;83: S164–S169.

70. Barkama R, Mayo A, Paz A, Solopov A, Mann T, Vadasz Z, Appel T, Ofir R, Shani L, Sheleg M, Allenet H, et al. Placenta-derived cell therapy to treat patients with respiratory failure due to coronavirus disease 2019. Crit Care Explor. 2020;2(9):e0207.

71. Khatri M, Saif YM. Influenza virus infects bone marrow mesenchymal stromal cells in vitro: implications for bone marrow transplantation. Cell Transplant. 2013;22(3):461–468.

72. Yim H, Jeong H, Cho Y, Jeong S. Safety of mesenchymal stem cell therapy: a systematic review and meta-analysis. Cytotherapy. 2016;18(6):S132.